Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|October 14, 2014
Gustave Roussy in Paris Links Up with New Oncology
Author(s)Philip Ward
New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.
Advertisement
New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.
Under this agreement, New Oncology will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows sample processing compatible with both daily clinical routine and standard sample material, i.e. FFPE (formalin-fixed, paraffin-embedded) tissue, according to the company.
Gustave Roussy is an international institute in oncology with a staff of 2,600 health professionals. By devoting 20% of its budget to research, it aims to promote research as an innovative engine for the benefit of patients. Gustave Roussy is a private health facility working within the French public health system and is authorized to receive donations and bequests.
“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Prof. Jean-Charles Soria, Head of the Drug Development Department at Gustave Roussy Cancer Campus.
“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients” commented Andreas Jenne, PhD, CEO of New Oncology, the molecular diagnostics division of Blackfield AG, a company specializing in cancer genome analysis.
New Oncology’s proprietary diagnostic platform ‘NEO’ enables physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. Its pan-cancer diagnostic test NEOplus detects actionable genetic alterations with short turn-around times and identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample, according to the vendor. It works with a tumor board comprising renowned cancer experts, facilitating translation of the latest findings in targeted therapy into optimized patient care.
Read the full release
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5